Klara Beitl1, Klara Rosta1, Nina Poetsch2, Manuel Seifried1, Daniel Mayrhofer1, Barbara Soliman1, Rodrig Marculescu3, Johannes Ott4. 1. Clinical Division of Gynecological Endocrinology and Reproductive Medicine, Department of Gynecological Endocrinology and Reproductive Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. 2. Department of Radiology and Nuclear Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. 3. Department of Laboratory Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. 4. Clinical Division of Gynecological Endocrinology and Reproductive Medicine, Department of Gynecological Endocrinology and Reproductive Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. johannes.ott@meduniwien.ac.at.
Abstract
PURPOSE: It is still not clear whether to screen women with primary premature ovarian insufficiency for autoimmunity. Moreover, a possible association of autoimmunity with decreased bone mass density in premature ovarian insufficiency patients has not been evaluated. Thus, the objectives of this study were to review our experience with the use of an autoimmune screening panel in premature ovarian insufficiency women and to focus on bone mass density. METHODS: In a retrospective cohort study, 76 chromosomally normal women with primary premature ovarian insufficiency were included. The main outcome parameters were the results of an autoimmune screening panel and of dual-energy X-ray absorptiometry. RESULTS: Median age was 33 years. Sixty percent of premature ovarian insufficiency patients revealed abnormal dual-energy X-ray absorptiometry results (minimal T-score < -1.0). Any signs of autoimmunity were found in 21 women (36.2%). The most frequent abnormal results were increased thyroperoxidase antibodies (24.1%) and thyroglobulin antibodies (20.7%). A longer duration of amenorrhea (β = -0.015; p = 0.007), any abnormality during autoimmune screening (β = -0.940; p = 0.010), and a lower body mass index (β = -0.057; p = 0.036) were associated with a lower minimal T-score. CONCLUSION: In chromosomally normal women with primary premature ovarian insufficiency, the prevalence of autoimmunity and decreased bone mass density seem high. Our data highlight the association between autoimmune abnormalities and decreased dual-energy X-ray absorptiometry results.
PURPOSE: It is still not clear whether to screen women with primary premature ovarian insufficiency for autoimmunity. Moreover, a possible association of autoimmunity with decreased bone mass density in premature ovarian insufficiencypatients has not been evaluated. Thus, the objectives of this study were to review our experience with the use of an autoimmune screening panel in premature ovarian insufficiencywomen and to focus on bone mass density. METHODS: In a retrospective cohort study, 76 chromosomally normal women with primary premature ovarian insufficiency were included. The main outcome parameters were the results of an autoimmune screening panel and of dual-energy X-ray absorptiometry. RESULTS: Median age was 33 years. Sixty percent of premature ovarian insufficiencypatients revealed abnormal dual-energy X-ray absorptiometry results (minimal T-score < -1.0). Any signs of autoimmunity were found in 21 women (36.2%). The most frequent abnormal results were increased thyroperoxidase antibodies (24.1%) and thyroglobulin antibodies (20.7%). A longer duration of amenorrhea (β = -0.015; p = 0.007), any abnormality during autoimmune screening (β = -0.940; p = 0.010), and a lower body mass index (β = -0.057; p = 0.036) were associated with a lower minimal T-score. CONCLUSION: In chromosomally normal women with primary premature ovarian insufficiency, the prevalence of autoimmunity and decreased bone mass density seem high. Our data highlight the association between autoimmune abnormalities and decreased dual-energy X-ray absorptiometry results.
Entities:
Keywords:
Autoimmunity; Bone mass density; Premature ovarian insufficiency
Authors: C De Laet; J A Kanis; A Odén; H Johanson; O Johnell; P Delmas; J A Eisman; H Kroger; S Fujiwara; P Garnero; E V McCloskey; D Mellstrom; L J Melton; P J Meunier; H A P Pols; J Reeve; A Silman; A Tenenhouse Journal: Osteoporos Int Date: 2005-06-01 Impact factor: 4.507
Authors: Tobias Schmidt; Constantin Schmidt; Andre Strahl; Haider Mussawy; Tim Rolvien; Nico M Jandl; Christian Casar; Ralf Oheim; Thorsten Schinke; Ansgar W Lohse; Michael Amling; Christoph Schramm; Florian Barvencik Journal: Clin Gastroenterol Hepatol Date: 2019-06-01 Impact factor: 11.382
Authors: Margaret L Gourlay; Jason P Fine; John S Preisser; Ryan C May; Chenxi Li; Li-Yung Lui; David F Ransohoff; Jane A Cauley; Kristine E Ensrud Journal: N Engl J Med Date: 2012-01-19 Impact factor: 91.245
Authors: Vaishali B Popat; Karim A Calis; Vien H Vanderhoof; Giovanni Cizza; James C Reynolds; Nancy Sebring; James F Troendle; Lawrence M Nelson Journal: J Clin Endocrinol Metab Date: 2009-04-28 Impact factor: 5.958
Authors: A Podfigurna-Stopa; A Czyzyk; M Grymowicz; R Smolarczyk; K Katulski; K Czajkowski; B Meczekalski Journal: J Endocrinol Invest Date: 2016-04-18 Impact factor: 4.256
Authors: Claudia Mendoza-Pinto; Adriana Rojas-Villarraga; Nicolás Molano-González; Erick A Jiménez-Herrera; María de la Luz León-Vázquez; Álvaro Montiel-Jarquín; Mario García-Carrasco; Ricard Cervera Journal: PLoS One Date: 2018-06-13 Impact factor: 3.240